Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Variants on the promoter region of PTEN affect breast cancer progression and patient survival

Figure 1

Kaplan-Meier plots of cumulative survival for breast cancer patients carrying a PTEN promoter variant. The plots for patients with different variants are shown for -903GA in green, -975GC in orange, -1026CA in red, and for non-carrier Wild type in blue. All variants showed significant long term survival effect in breast cancer specific 10-year analyses (A) with cumulative survival at 120 months of 82.7% (95% CI 80.7 to 84.7%) for non-carriers, 71.3% (95% CI 58.8 to 83.8%) for -903GA (P = 0.016), 57.2% (95% CI 33.1 to 81.3%) for -975GC (P = 0.002), and 65.3% (95% CI 47.1 to 83.5%) for -1026CA (P = 0.014). Two variants also showed significant effect in five year breast cancer death or distant metastasis free analysis (B) with cumulative survival at 60 months of 82.5% (95% CI 80.7 to 84.3%) for non-carriers, 64.3% (95% CI 51.2 to 77.3%) for -903GA (P = 0.002), 63.8% (95% CI 44.4 to 83.2%) for -975GC (P = 0.010), and 76.9% (95% CI 62.6 to 91.0%) for -1026CA (P = 0.279).

Back to article page